Reaction

Lung Abscess reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,062 reports · 73 co-occurring drugs

As of the last recalculation, Lung Abscess appears in 2,062 FAERS reports alongside 73 co-occurring drug terms. The strongest observed disproportionality signal is GANCICLOVIR (PRR 19.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ganciclovir	20	19.9	19.9
Ganciclovir Sodium	20	19.3	19.3
Voriconazole Injection	39	18.5	18.5
Voriconazole	45	15.3	15.3
Atovaquone	11	13.9	13.9
Amikacin	23	13.8	13.8
Piperacillin Sodium,Tazobactam Sodium	34	13.1	13.2
Remdesivir	16	12.2	12.2
Rifampicin	12	12.0	12.1
Ceftriaxone	36	11.3	11.3
Meropenem	35	11.2	11.2
Ceftriaxone Sodium	40	10.7	10.7
Tobramycin Sulfate	13	10.7	10.7
Prednisolone	173	10.5	10.5
Prednisolone Oral	173	10.5	10.5
Prednisolone Oral Solution	173	10.5	10.5
Basiliximab	12	10.4	10.4
Tobramycin Solution	12	10.1	10.1
Tofacitinib Citrate	13	10.1	10.1
Piperacillin Sodium And Tazobactam Sodium	19	9.9	9.9
Granisetron Hydrochloride	10	9.7	9.7
Micafungin Sodium	8	9.6	9.6
Daspone	9	9.4	9.4
Dapsone Gel, 5%	9	9.4	9.4
Sirolimus	12	9.0	9.0
Amphotericin B	11	8.9	8.9
Meperidine Hydrochloride	8	8.8	8.8
Piperacillin And Tazobactam	11	8.7	8.7
Dapsone	9	8.5	8.5
Azathioprine	72	8.5	8.5
Posaconazole Delayed-Release	9	8.3	8.3
Lumacaftor And Ivacaftor	7	8.3	8.3
Durvalumab	16	8.0	8.0
Mycophenolate Mofetil	102	7.9	7.9
Mycophenolate Mofetil Hydrochloride	102	7.9	7.9
Ivacaftor	6	7.6	7.6
Posaconazole	12	7.5	7.5
Tacrolimus Ointment 0.1%	88	7.4	7.4
Tacrolimus Extended-Release Capsules	88	7.4	7.4
Tobramycin	17	7.2	7.2
Tacrolimus	101	6.8	6.8
Granisetron	7	6.8	6.8
Paclitaxel	63	6.6	6.6
Paclitaxel (Aibumin-Bound)	52	6.5	6.5
Busulfan	10	6.4	6.4
Atezolizumab	24	6.3	6.3
Carboplatin	76	6.2	6.2
Vancomycin Hydrochloride	39	6.1	6.1
Lenvatinib	19	5.9	5.9
Dornase Alfa	11	5.7	5.7
Cisplatin	42	5.5	5.5
Sorafenib	11	5.4	5.4
Thiotepa	5	5.3	5.3
Etoposide	37	5.2	5.2
Cabozantinib	24	5.1	5.1
Nivolumab	47	5.0	5.0
Bleomycin Sulfate	5	4.9	4.9
Tenofovir Disoproxil Fumarate Tablets	4	4.7	4.7
Alpelisib	4	4.6	4.6
Pembrolizumab	45	4.4	4.4
Clozapine	52	4.3	4.3
Polatuzumab Vedotin	4	4.1	4.1
Pegaspargase	5	4.1	4.1
Azacitidine	12	4.1	4.1
Elexacaftor, Tezacaftor, And Ivacaftor	5	4.1	4.1
Cetuximab	12	3.9	3.9
Docetaxel Anhydrous	23	3.5	3.5
Docetaxel	23	3.5	3.5
Budesonide, Glycopyrrolate, And Formoterol Fumarate	3	2.9	2.9
Daratumumab	11	2.8	2.8
Osimertinib	7	2.2	2.2
Bimekizumab	4	1.9	1.9
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	4	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.